Stockscreener 앱 받기
6.50
3.35%
-0.225
전일 마감가:
$6.725
열려 있는:
$6.87
하루 거래량:
3.22M
Relative Volume:
1.22
시가총액:
$700.31M
수익:
-
순이익/손실:
$-258.08M
주가수익비율:
-2.3636
EPS:
-2.75
순현금흐름:
$-202.32M
1주 성능:
-7.01%
1개월 성능:
+5.69%
6개월 성능:
-53.51%
1년 성능:
-72.22%
1일 변동 폭
$6.36
$6.87
1주일 범위
$5.72
$7.39
52주 변동 폭
$4.55
$26.98
Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile
명칭
Rocket Pharmaceuticals Inc
전화
646-440-9100
주소
350 FIFTH AVENUE, NEW YORK, NY
RCKT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RCKT
Rocket Pharmaceuticals Inc
|
6.50 | 753.09M | 0 | -258.08M | -202.32M | -2.75 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-12 | 개시 | BMO Capital Markets | Outperform |
| 2024-12-30 | 개시 | Wedbush | Outperform |
| 2024-12-18 | 개시 | Jefferies | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-04-02 | 개시 | Goldman | Neutral |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-02-01 | 개시 | Morgan Stanley | Overweight |
| 2022-11-08 | 개시 | Canaccord Genuity | Buy |
| 2022-11-01 | 개시 | BTIG Research | Buy |
| 2022-07-08 | 개시 | Raymond James | Outperform |
| 2021-10-20 | 재개 | Cowen | Outperform |
| 2021-03-02 | 개시 | Stifel | Buy |
| 2021-02-18 | 개시 | Needham | Buy |
| 2020-12-16 | 개시 | UBS | Buy |
| 2020-12-08 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-07-02 | 개시 | JP Morgan | Overweight |
| 2020-06-25 | 재개 | BofA/Merrill | Buy |
| 2020-06-01 | 재개 | Oppenheimer | Outperform |
| 2019-11-06 | 개시 | Chardan Capital Markets | Buy |
| 2019-09-26 | 개시 | Piper Jaffray | Overweight |
| 2019-04-23 | 개시 | Robert W. Baird | Outperform |
| 2019-03-15 | 개시 | BofA/Merrill | Buy |
| 2019-02-05 | 개시 | Oppenheimer | Outperform |
| 2018-09-13 | 개시 | Ladenburg Thalmann | Buy |
| 2018-07-10 | 개시 | William Blair | Outperform |
모두보기
Rocket Pharmaceuticals Inc 주식(RCKT)의 최신 뉴스
Rocket Pharmaceuticals Presents Preliminary Data from Phase 1 Cl - GuruFocus
Rocket Pharma's Gene Therapy Shows Promise in ACM Patients, Says Analyst - Benzinga
Rocket Pharmaceuticals (RCKT) Price Target Raised by Cantor Fitzgerald | RCKT Stock News - GuruFocus
Rocket Pharmaceuticals (RCKT) Price Target Maintained by Wedbush - GuruFocus
Is Rocket Pharmaceuticals (RCKT) the Best Low Priced Biotech Stock to Buy Now? - MSN
Rocket Pharmaceuticals (RCKT) Sees Price Target Boost Amid Positive Trial Data | RCKT Stock News - GuruFocus
Chardan Ups Price Target on Rocket Pharmaceuticals to $46 From $45, Maintains Buy Rating - marketscreener.com
Chardan Ups Price Target for Rocket Pharmaceuticals (RCKT) | RCKT Stock News - GuruFocus
Rocket Pharmaceuticals (RCKT) Price Target Raised by Chardan Cap - GuruFocus
Transcript : Rocket Pharmaceuticals, Inc.Special Call - marketscreener.com
Rocket Pharma reports promising RP-A601 gene therapy trial results - Investing.com
Rocket Pharmaceuticals Presents Preliminary Data From Phase 1 Clinical Trial of RP-A601 For PKP2 Arrhythmogenic Cardiomyopathy At 28th Annual Meeting Of The American Society Of Gene And Cell Therapy - marketscreener.com
Rocket Pharmaceuticals (RCKT) Phase 1 Trial Yields Promising Results | RCKT Stock News - GuruFocus
Rocket Pharmaceuticals Presents Preliminary Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy at 28th Annual Meeting of the American Society of Gene and Cell Therapy - BioSpace
Rocket Pharmaceuticals (RCKT) Presents Preliminary Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy - StreetInsider
Fanconi anemia Pipeline 2025: Groundbreaking Clinical - openPR.com
Research Analysts Set Expectations for RCKT FY2025 Earnings - Defense World
(RCKT) Investment Analysis - news.stocktradersdaily.com
Rocket Pharmaceuticals (NASDAQ:RCKT) Trading Down 7.5% Following Analyst Downgrade - Defense World
Wellington Management Group LLP Reduces Stake in Rocket Pharmace - GuruFocus
Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target Lowered to $34.00 at Canaccord Genuity Group - Defense World
Canaccord Revises Rocket Pharmaceuticals (RCKT) Price Target Ami - GuruFocus
The Goldman Sachs Group Cuts Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target to $13.00 - Defense World
Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target Lowered to $51.00 at Scotiabank - Defense World
Promising Early-Stage Data and Strategic Adaptations Justify Buy Rating for Rocket Pharmaceuticals - TipRanks
RCKT: Scotiabank Lowers Price Target for Rocket Pharmaceuticals to $51 | RCKT Stock News - GuruFocus
Scotiabank Adjusts Price Target for Rocket Pharmaceuticals (RCKT - GuruFocus
Rocket Pharmaceuticals (RCKT) Maintains 'Buy' Rating Despite PT Reduction | RCKT Stock News - GuruFocus
10 Best Low-Priced Biotech Stocks to Buy Now - Insider Monkey
22,645 Shares in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Purchased by Raymond James Financial Inc. - Defense World
JPMorgan Chase & Co. Cuts Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target to $44.00 - Defense World
Chardan Capital Cuts Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target to $45.00 - Defense World
Dimensional Fund Advisors LP Has $9.57 Million Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Rocket Pharmaceuticals (RCKT) Sees Price Target Adjustment by JP Morgan | RCKT Stock News - GuruFocus
Rocket Pharmaceuticals Announces Late-Breaking Oral Presentation - GuruFocus
Chardan Capital Lowers Price Target for RCKT to $45, Maintains B - GuruFocus
Rocket Pharmaceuticals (RCKT) Price Target Lowered by Goldman Sa - GuruFocus
Chardan Capital Lowers Price Target for RCKT to $45, Maintains Buy Rating | RCKT Stock News - GuruFocus
Rocket Pharmaceuticals Announces Late-Breaking Oral Presentation of Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy Accepted at 28th Annual Meeting of the American Society of Gene and Cell Therapy - Business Wire
Rocket Pharmaceuticals (RCKT) Price Target Lowered by Goldman Sachs | RCKT Stock News - GuruFocus
RCKT's Q1 Loss Narrower Than Expected, Pipeline in Focus - sharewise
Rocket Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks
JPMorgan Adjusts Price Target for Rocket Pharmaceuticals (RCKT) | RCKT Stock News - GuruFocus
Mariner LLC Takes $139,000 Position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - Defense World
Rocket Pharmaceuticals: Q1 Earnings Snapshot - Norwalk Hour
Rocket Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Progress - BioSpace
Rocket Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Post-Trade Analysis: Rocket Pharmaceuticals Inc (RCKT) Slides -19.62, Closing at 6.31 - DWinneX
Citizen Health Partner to Support Drug Development and Long-Term Patient Outcomes in PKP2 Cardiomyopathy - Morningstar
Rocket Pharmaceuticals Inc (RCKT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.54%
7.58%
자본화:
|
볼륨(24시간):